The Division will be sponsoring the following meeting to address the Preferred Drug List.

Please note, this meeting will be available via teleconference only.

See registration instructions at the bottom of the page.

The Pharmacy and Therapeutics Committee will meet Friday, January 17, 2025 at 8:00 a.m. Agendas are posted on the Health Care Services Preferred Drug List Program Overview website https://health.alaska.gov/dhcs/Pages/pdl/default.aspx

Any pharmaceutical manufacturer may submit unsolicited material related to the agenda items by utilizing the Clinical Submission form. Clinical Submissions will be accepted until January 3, 2025 at 4:00pm AK local time. Forms may be found at: https://health.alaska.gov/dhcs/Documents/pdl/Documents/AK_Submission_Request_Form_for_Pharmaceutical_Manufacturers.pdf

Any member of the public, including health care professionals, may submit unsolicited material related to the agenda items, by utilizing the Clinical Submission form found at: https://health.alaska.gov/dhcs/Pages/pdl/download_pdl.aspx

A conflict of interest form must accompany any submission and can be found at:  https://health.alaska.gov/dhcs/Documents/pharmacy/forms/Alaska-Medicaid-Clinical-Coverage-Review-Request-Disclosure-Form.pdf Submissions should be received no later than January 15, 2025 to allow inclusion in the meeting. If you cannot join the webinar and would like to join via teleconference, please dial 1.844-730-9010 (Toll Free) Webinar ID: 130 491 615#

Individuals with disabilities who need special accommodations in order to participate should contact Matthew Parrott at 907.334.2425 no later than 2:00 p.m., Wednesday, January 15, 2025.

Public Teams Connection Instructions

You are invited to a Prime Therapeutics webinar.

When: January 17, 2025 08:00 AM Alaska

Topic: AK P&T Committee Meeting

Please register by clicking the link below:

https://events.teams.microsoft.com/event/d0fafec0-a9eb-4bab-b4a8-fe561a4ffd26@34c95ba7-5ec6-4527-bc5e-b33b58104992

After registering, you will receive a confirmation email containing information about joining the webinar.

This meeting is being recorded.

If you are a member of the public, a healthcare professional, or an industry representative and wish to provide public comment at the meeting today, please send the following information via the Chat function to the host:
    1. Name and credentials (if applicable)
    2. Who you are representing/affiliation(s)) (company, self, organization, group)
    3. The drug class for which you wish to provide public comment
    4. Any conflict of interest disclosure (i.e., financial affiliations with the topic you are presenting on)

The Chair will call on pharmaceutical industry representatives during the appropriate class discussion. If you are an Alaskan healthcare professional (not affiliated with industry), the chair will provide an opportunity at the beginning of the meeting for comments.

Note that while the CMS Open Payments database is used to identify potential conflicts of interest, it is the speaker's responsibility to disclose any conflicts of interest prior to addressing the committee.

All industry presentations (limited to 3 min) must be consistent with Federal regulation; any misrepresentation of products discussed by pharmaceutical representatives will be reported to the FDA's Office of Prescription Drug Promotion.

https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/opdp-regulatory-information 

Written comments for this meeting may be sent to Matt Parrott at matthew.parrott@alaska.gov.